SCHEMBL5004871

SCHEMBL5004871

CCOc1ccc(-n2c(C)cc(C(C)=O)c2C)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 6/20 0.53
MAPK1 P28482 1/20 0.53
ALDH1A1 P00352 6/20 0.53
LMNA P02545 4/20 0.53
MAPT P10636 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
MEN1 O00255 2/20 0.53
MITF O75030 2/20 0.53
KMT2A Q03164 2/20 0.53
HKDC1 Q2TB90 2/20 0.53
HTT P42858 3/20 0.51
GFER P55789 1/20 0.51
RORC P51449 1/20 0.47
HPGD P15428 2/20 0.47
PTBP1 P26599 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
MYC P01106 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5004961 0.83 ALDH1A1 (0.62) MAPK1ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL5004534 0.80 MAPT (0.74) NOTUMMAPK1ALDH1A1LMNAMAPT
SCHEMBL5004793 0.79 MAPT (0.49) ALDH1A1LMNAMAPTSMN1; SMN2MEN1
SCHEMBL10372395 0.72 NOTUM (0.75) NOTUMMAPK1ALDH1A1LMNAMAPT
SCHEMBL5001005 0.71 CACNA2D1 (0.61) ALDH1A1MAPTMEN1KMT2A
SCHEMBL8204769 0.70 CREBBP (0.66) MAPK1ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL5004706 0.69 ALDH1A1 (0.65) MAPK1ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL21387140 0.69 NOTUM (0.77) NOTUMALDH1A1LMNASMN1; SMN2HTT
SCHEMBL5004589 0.69 NOTUM (0.53) NOTUMMAPK1ALDH1A1LMNAMAPT
SCHEMBL5005526 0.69 NOTUM (0.50) NOTUMMAPK1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465730-B2 Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds MERCK & CO. INC. (US) 2008-12-16 US disclosed
US-20060154929-A1 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds MERCK SHARP & DOHME CORP. 2006-07-13 US disclosed
EP-1539168-A2 TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO(3,4-D)PYRIDAZINE COMPOUNDS Merck & Co., Inc. (US) 2005-06-15 EP disclosed
WO-2004006836-A2 TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO[3,4-D]PYRIDAZINE COMPOUNDS MERCK & CO., INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154929-A1 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds GRIN2C, CACNA1C, CACNG4 NOTUM 3922/4885MAPK1 3323/4885ALDH1A1 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.